CD274 and neoplasm: In tumour with negative PD-L1 expression, median OS was 6.05 months in nivolumab arm (versus 4.19 months in the placebo arm; hazard ratio 0.72); in patients with PD-L1 expression ≥1%, median OS was 5.22 months in the arm of nivolumab (versus 3.83 months in the placebo arm; hazard ratio 0.51).